Marc Diamond, MD
Pulmonary Disease · Philadelphia, PANPI 1760613665
Payments from drug & device makers
Across 43 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$574
- Insmed, Inc.$91
- Philips North America LLC$89
- Teva Pharmaceuticals USA, Inc.$75
- Resmed Corp$71
- Genentech USA, Inc.$57
- plus $77 from 3 others
What the payments were for
- Food & beverage$93590%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 19 | $574 |
| Insmed, Inc. | 5 | $91 |
| Philips North America LLC | 5 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Resmed Corp | 4 | $71 |
| Genentech USA, Inc. | 3 | $57 |
| Advanced Respiratory, Inc | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Nabriva Therapeutics, PLC | 1 | $24 |
How this compares
$1,035 in reported general payments places this provider in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $93,880 |
| NucalaMepolizumab | 26 | $92,897 |
| Dupixent PenDupilumab | 17 | $62,085 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $50,325 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $44,267 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $31,508 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $16,397 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $7,124 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,742 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $5,551 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,368 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $3,669 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,435 |
| Montelukast Sodium | 85 | $867 |
| Levocetirizine Dihydrochloride | 22 | $558 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$18.2M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Steven KelsenPhiladelphia$847K
- Parth RaliPhiladelphia$814K
- Kartik ShenoyPhiladelphia$701K
- Christopher ManleyPhiladelphia$580K
- Michaela AndersonPhiladelphia$515K
- Michael BaramPhiladelphia$501K
- Ross SummerPhiladelphia$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.